How to buy AstraZeneca (AZN) shares

Learn how to easily invest in AstraZeneca shares.

On December 30 2020 the Oxford-AstraZeneca vaccine was approved for use in the UK. There will be more than 500,000 doses available and the vaccine is easier to store and distribute than the Pfizer-BioNTech vaccine. This will, no doubt, have an impact on the share price of the company. Investors are likely to buy shares with the hope that the share price of AstraZeneca will rise following this news and the hope that the vaccine will be approved for use in other countries worldwide.

AstraZeneca PLC (AZN) is a publicly traded drug manufacturers-general business based in the UK. It opened the day at 9935p after a previous close of 9923p. During the day the price has varied from a low of 9818p to a high of 10076p. The latest price was 10076p (25 minute delay). AstraZeneca is listed on the London Stock Exchange (LSE) and employs 83,100 staff. All prices are listed in pence sterling.

How to buy shares in AstraZeneca

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AZN in this case.
  5. Research AstraZeneca shares. The platform should provide the latest information available.
  6. Buy your AstraZeneca shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Fees for buying 5x AstraZeneca shares with popular platforms

Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £0.00
£503.80 total
Capital at risk
IG Share Dealing logo £0 £250 £8.00
£511.80 total
Capital at risk
Fineco logo £0 No minimum £0.00
£503.80 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £11.95
£515.75 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £1.82
£505.62 total
Capital at risk
Freetrade logo £0 £1 £0.00
£503.80 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £7.99
£511.79 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £9.50
£513.30 total
Capital at risk

Full comparison of share dealing platforms

AstraZeneca share price (LSE:AZN)

Use our graph to track the performance of AZN stocks over time.

AstraZeneca price performance over time

Historical closes compared with the last close of 10076p

1 week (2022-09-22) 1.43%
1 month (2022-08-26) -11.33%
3 months (2022-06-29) -8.85%
6 months (2022-03-29) 0.30%
1 year (2021-09-28) 18.90%
2 years (2020-09-29) 18.00%
3 years (2019-09-27) 36.48%
5 years (2017-09-29) 103.35%

Is it a good time to buy AstraZeneca stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Promoted
eToro Free Stocks

Invest in AstraZeneca shares with 0% commission

  • Start investing from as little as $10
  • Pay no stamp duty on UK shares
  • Join 25 million users who trust their investments with eToro
Other fees apply. Capital at risk

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is AstraZeneca under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

PEG ratio

AstraZeneca's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2027. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider AstraZeneca's PEG ratio in relation to those of similar companies.

EBITDA

AstraZeneca's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping £12.5 billion.

The EBITDA is a measure of a AstraZeneca's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AstraZeneca.

Total ESG risk score

AstraZeneca's total ESG risk: 28.52

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AstraZeneca's overall score of 28.52 (as at 01/01/2019) is nothing to write home about – landing it in it in the 45th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like AstraZeneca is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare AstraZeneca's total ESG risk score against those of similar companies.

Environmental score

AstraZeneca's environmental score: 0.19/100

AstraZeneca's environmental score of 0.19 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that AstraZeneca is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

AstraZeneca's social score: 15.45/100

AstraZeneca's social score of 15.45 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that AstraZeneca is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

AstraZeneca's governance score: 8.88/100

AstraZeneca's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that AstraZeneca is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

AstraZeneca's controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, AstraZeneca scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AstraZeneca hasn't always managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

AstraZeneca PLC was last rated for ESG on: 2019-01-01.

Total ESG score 28.52
Total ESG percentile 44.72
Environmental score 0.19
Environmental score percentile 3
Social score 15.45
Social score percentile 3
Governance score 8.88
Governance score percentile 3
Level of controversy 3

AstraZeneca shares at a glance

Information last updated 2022-09-28.
Open9935p
High10076p
Low9818p
Close10076p
Previous close9923p
Change153p
Change %1.5419%
Volume2,463,414
Information last updated 2022-09-24.
52-week range8087.8553p - 11540p
50-day moving average10738.96p
200-day moving average9906.04p
Wall St. target price119.34p
Dividend yield290p (2.2%)
Earnings per share (TTM)-58.8p

AstraZeneca share dividends

2.2%

Dividend yield: 2.2% of stock value

2.2%

Forward annual dividend yield: 2.2% of stock value

34.9%

Dividend payout ratio: 34.86% of net profits

AstraZeneca has recently paid out dividends equivalent to 2.20% of its share value annually.

AstraZeneca has paid out, on average, around 34.86% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.2% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 2.2% return on their shares, in the form of dividend payments. In AstraZeneca's case, that would currently equate to about 290p per share.

While AstraZeneca's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.

The latest dividend was paid out to all shareholders who bought their shares by 11 August 2022 (the "ex-dividend date").

AstraZeneca's dividend yield is perhaps best considered in relation to those of similar companies.

Share price volatility

Over the last 12 months, AstraZeneca's shares have ranged in value from as little as 8087.8553p up to 11540p. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while AstraZeneca's is 0.1294. This would suggest that AstraZeneca's shares are less volatile than average (for this exchange).

To put AstraZeneca's beta into context you can compare it against those of similar companies.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site